Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma.

about

Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma.

Item

http://www.wikidata.org/entity/Q47130656

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Italian real life experience w ...... refractory Hodgkin's lymphoma.

@en

Italian real life experience w ...... refractory Hodgkin's lymphoma.

@nl

type

Item

label

Italian real life experience w ...... refractory Hodgkin's lymphoma.

@en

Italian real life experience w ...... refractory Hodgkin's lymphoma.

@nl

prefLabel

Italian real life experience w ...... refractory Hodgkin's lymphoma.

@en

Italian real life experience w ...... refractory Hodgkin's lymphoma.

@nl

P1476

Italian real life experience w ...... refractory Hodgkin's lymphoma.

@en

P2093

Alessandra Romano

http://www.w3.org/2001/XMLSchema#string

Alessandro Broccoli

http://www.w3.org/2001/XMLSchema#string

Alessandro Pulsoni

http://www.w3.org/2001/XMLSchema#string

Amalia De Renzo

http://www.w3.org/2001/XMLSchema#string

Angelo Fama

http://www.w3.org/2001/XMLSchema#string

Angelo Michele Carella

http://www.w3.org/2001/XMLSchema#string

Anna Marina Liberati

http://www.w3.org/2001/XMLSchema#string

Anna Vanazzi

http://www.w3.org/2001/XMLSchema#string

Antonello Pinto

http://www.w3.org/2001/XMLSchema#string

Barbara Botto

http://www.w3.org/2001/XMLSchema#string

P2860

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia.

Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey.

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.

Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma

Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma

Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.

Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

P304

91703-91710

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.18114

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29207679

http://www.w3.org/2001/XMLSchema#string

P932

5710959

http://www.w3.org/2001/XMLSchema#string